(OTC Pink:GOGC)(OTC Pink:GOGC)

Forward-Looking Forward-Looking StatementStatement

This presentation contains statements that constitute This presentation contains statements that constitute ““forward-lookingforward-looking”” statements within statements withinthe meaning of the Securities Act of 1993 and the Securities Exchange Act of 1934, as the meaning of the Securities Act of 1993 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. amended by the Private Securities Litigation Reform Act of 1995. ““Forward-lookingForward-looking”” statements contained in this presentation include the intent, belief or current expectationsstatements contained in this presentation include the intent, belief or current expectationsof the Company and its senior management team with respect to future actions by the of the Company and its senior management team with respect to future actions by the Company, prospects of the CompanyCompany, prospects of the Company’’s operations, profits from future operations, overall s operations, profits from future operations, overall future business prospects and long-term stockholder value, as well as the assumptions future business prospects and long-term stockholder value, as well as the assumptions upon which such statements are based.upon which such statements are based.

Investors are cautioned that any such Investors are cautioned that any such ““forward-lookingforward-looking”” statements are not guarantees of statements are not guarantees offuture performance, and that actual results may differ materially from those contemplated future performance, and that actual results may differ materially from those contemplated by such by such ““forward-lookingforward-looking”” statements. Important factors currently known to management statements. Important factors currently known to managementthat could cause actual results to differ materially from those contemplated by the that could cause actual results to differ materially from those contemplated by the ““forward-lookingforward-looking”” statement in this presentation include, but are not limited to, adverse statement in this presentation include, but are not limited to, adversedevelopments involving operations of the Companydevelopments involving operations of the Company’’s business units, failure to meet s business units, failure to meet operating objectives or to execute the business plan, the failure to reach revenue or profit operating objectives or to execute the business plan, the failure to reach revenue or profit projections and the failure to retain and hire key personnel and management. The projections and the failure to retain and hire key personnel and management. The Company undertakes no obligation to update or revise the Company undertakes no obligation to update or revise the ““forward-lookingforward-looking”” statements statements contained in this presentation to reflect changed assumptions, the occurrence of contained in this presentation to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.unanticipated events, or changes to future operating results over time.

Corporate Corporate DescriptionDescription

Global Green, Inc. introduces Global Green, Inc. introduces Salmogenics™,Salmogenics™,

a new patented vaccine to help combat a new patented vaccine to help combat the dangerous effects that Salmonella the dangerous effects that Salmonella

bacteria produce in animals and human bacteria produce in animals and human beings. Global Green, upon USDA beings. Global Green, upon USDA

approval, plans to manufacture, market approval, plans to manufacture, market and sell and sell

the vaccine in the poultry industry. the vaccine in the poultry industry.

A unique, new patented vaccine to A unique, new patented vaccine to combat the devastating effects of combat the devastating effects of

SalmonellaSalmonella

Why This Vaccine?Why This Vaccine?

No Live Injection

In-Ovo Injection

Healthier Chicken

Company HighlightsCompany Highlights

Worldwide Market OpportunityWorldwide Market Opportunity Exclusive Rights to Two Patents Owned by Exclusive Rights to Two Patents Owned by

N.H.I.L., a research affiliate and majority N.H.I.L., a research affiliate and majority shareholdershareholder

Only Source of New Patented Vaccine Offering: Only Source of New Patented Vaccine Offering: Protection from deadly Salmonella bacteriaProtection from deadly Salmonella bacteria Healthier protein source Healthier protein source Potential to improve the lives of millions of peoplePotential to improve the lives of millions of people

Product Expansion PotentialProduct Expansion Potential

AgendaAgenda

Market OpportunityMarket Opportunity

Business StrategyBusiness Strategy

Market Market OpportunityOpportunity

Market OverviewMarket Overview Approximately 1.3 billion humans Approximately 1.3 billion humans

contract salmonella annually, with 2-3 contract salmonella annually, with 2-3 million resulting in deathmillion resulting in death

1 million humans in the U.S. contract 1 million humans in the U.S. contract salmonella annuallysalmonella annually

40 billion chickens will benefit from 40 billion chickens will benefit from the salmonella vaccinethe salmonella vaccine

Salmonella is the scientific name for Salmonella is the scientific name for over 2,500 types of bacteriaover 2,500 types of bacteria

The Problem is PublicThe Problem is Public““Salmonella is common in poultry, so Salmonella is common in poultry, so

itit’’s not illegal fors not illegal for meat to be tainted with the pathogen.meat to be tainted with the pathogen.””

CBS News, August 2011CBS News, August 2011

““For every laboratory-confirmed case of For every laboratory-confirmed case of Salmonella, there are at least 29 Salmonella, there are at least 29

unreported cases.unreported cases.”” Centers for Disease Centers for Disease Control, 2011Control, 2011

2010 USDA Mandate2010 USDA MandateReduce the percentage of Reduce the percentage of

Salmonella infected chicken Salmonella infected chicken allowed on the market from 7% allowed on the market from 7%

to 5%to 5%

Salmogenics has been shown in Salmogenics has been shown in efficacy studies to help accomplish efficacy studies to help accomplish

these strict requirementsthese strict requirements

USDA Approval ProgressUSDA Approval Progress

In last stages of testing and trialsIn last stages of testing and trials Vaccine proven to be safe, non-toxic Vaccine proven to be safe, non-toxic

and causes no harm to the animal and causes no harm to the animal Studies to date conclude that Studies to date conclude that

Salmogenics reduces Salmonella Salmogenics reduces Salmonella contaminationcontamination

USDA Final Phase StatusUSDA Final Phase Status Identify and contract USDA-approved Identify and contract USDA-approved

vaccine manufacturervaccine manufacturer Assure requirements from the vaccine Assure requirements from the vaccine

manufacturer will meet USDA requirementsmanufacturer will meet USDA requirements Conclusion submitted to USDA must specify:Conclusion submitted to USDA must specify:

vaccine product can be safely and standardly vaccine product can be safely and standardly commercially applied by the intended customerscommercially applied by the intended customers

claims are sustainable and reproducible when claims are sustainable and reproducible when applied to larger populations of birdsapplied to larger populations of birds

vaccine can be used in other circumstances such vaccine can be used in other circumstances such as a combined treatment with other vaccinesas a combined treatment with other vaccines

Submit final results to USDA for approvalSubmit final results to USDA for approval

A A provenproven solution to reducing the solution to reducing the incidence and prevalence of incidence and prevalence of Salmonella in poultry, which can Salmonella in poultry, which can cause food poisoning in humanscause food poisoning in humans

Changes the Changes the approach approach to the to the control of the spread of an control of the spread of an economically devastating diseaseeconomically devastating disease

Organic Poultry Retail Organic Poultry Retail Market SalesMarket Sales

0

100

200

300

400

500

600

2005 2010

$161 Million

Source: USDA

$600Million

Source: Dolcera Analysis

Key Growth DriversKey Growth DriversPoultry Vaccine MarketPoultry Vaccine Market

(Estimated to be $5.4 billion by 2015)(Estimated to be $5.4 billion by 2015)

Growth of diseases in animalsGrowth of diseases in animals Increasing public awarenessIncreasing public awareness Technological advancementsTechnological advancements Ability of vaccines toAbility of vaccines to

Promote growthPromote growth Develop immunity against diseasesDevelop immunity against diseases Lower animal mortality rateLower animal mortality rate

Source: Global Industry Analysts

Potential Problems with Water Potential Problems with Water Borne or Spray Vaccinations Borne or Spray Vaccinations

with Chickenswith Chickens Multiple poultry caretakers involvedMultiple poultry caretakers involved Variety of vaccination equipment usedVariety of vaccination equipment used Re-use of containers = vaccine residuesRe-use of containers = vaccine residues Defective vaccine distribution patternsDefective vaccine distribution patterns Mixing vaccines for a complete dayMixing vaccines for a complete day Incorrect dosage of vaccine or diluentIncorrect dosage of vaccine or diluent

End ResultEnd Result::Added human interactions + labor costs + Added human interactions + labor costs +

stressstresson poultryon poultry

Advantages of In Ovo Vaccinations

Earlier immunityEarlier immunity Uniform deliveryUniform delivery Fast deliveryFast delivery Reduced stressReduced stress Reduced labor Reduced labor

costscosts Future productsFuture products

Egg Yolk Needle

Air ChamberShell

The Global Green The Global Green AdvantageAdvantage

is is SignificantSignificant•Earlier immunity•Uniform delivery•Fast delivery•Reduced stress•Reduced labor costs•Improved productivity•Future products

Benefits to the Entire Benefits to the Entire SystemSystem

Poultry GrowersPoultry Growers Fast deliveryFast delivery Uniform delivery systemUniform delivery system Reduced labor costs for Reduced labor costs for

inoculationinoculation

ChickenChicken Less traumaLess trauma Earlier immunity from Earlier immunity from

SalmonellaSalmonella

HumansHumans Healthier protein sourceHealthier protein source

EnvironmentEnvironment Environmentally Environmentally

friendlyfriendly

Food Service Handlers Reduced Reduced contaminationcontamination Healthier customers Healthier customers and and familiesfamilies

OtherVaccines

LiveBird

Incompatible with Marek’s Disease VaccineIncreased

Cost

Non-Standardized Dosage Delivery

More Susceptible to Secondary Infections

Labor Intensive

Trauma

Less Cost, Higher Conversion, Healthier Humans

Salmogenics In Ovo

Improved Conversion

Reduced

Cost

No Trauma

Early Immunity

Uniform Delivery

Compatible with Marek’s Disease Vaccine

Additional Market Applications

Salmogenics = Safer Egg

Worldwide egg market =

1.3 trillion eggs per year

+

Business Business StrategyStrategy

Business StrategyBusiness Strategy Complete final requirements for USDA approvalComplete final requirements for USDA approval Receive final approval by USDAReceive final approval by USDA Develop marketing and sales structure to Develop marketing and sales structure to

effectively convert market to Salmogenicseffectively convert market to Salmogenics Establish Salmogenics as standard in the Establish Salmogenics as standard in the

industryindustry Innovate through internal new product Innovate through internal new product

developmentdevelopment Establish a leadership position in vaccine Establish a leadership position in vaccine

technology with Salmogenics as the foundationtechnology with Salmogenics as the foundation

Top 10 Broiler Chicken Top 10 Broiler Chicken CompaniesCompanies

Representing 73.7% of Chickens Processed AnnuallyRepresenting 73.7% of Chickens Processed Annually#1#1 Tyson Foods, Inc.Tyson Foods, Inc.#2#2 PilgrimPilgrim’’s Pride Corp.s Pride Corp.#3#3 Perdue Farms, Inc.Perdue Farms, Inc.#4#4 Sanderson Farms, Inc.Sanderson Farms, Inc.#5#5 Koch Foods, Inc.Koch Foods, Inc.#6#6 Wayne Farms, LLCWayne Farms, LLC#7#7 Mountainaire Farms, Inc.Mountainaire Farms, Inc.#8#8 House of Raeford Farms, Inc.House of Raeford Farms, Inc.#9#9 Foster Farms, Inc.Foster Farms, Inc.#10#10 Peco Foods, Inc.Peco Foods, Inc.Source:Source: Watt PoultryUSA Feb 2010Watt PoultryUSA Feb 2010

PastDeveloped Salmogenics vaccine

PresentIntense focus on sales and marketing strategy is gaining traction

FutureGrowth and profitability

Global Green Evolution and Growth Trajectory

Market Penetration Market Penetration StrategiesStrategies

Strong and reliable regulatory approvalsStrong and reliable regulatory approvals Research data publicationsResearch data publications Company and product name recognitionCompany and product name recognition Advertising in leading publicationsAdvertising in leading publications

Animal productionAnimal production Food safetyFood safety

Strong and experienced technical staff Strong and experienced technical staff working with poultry industry expertsworking with poultry industry experts

Strong sales force focusing on top tier Strong sales force focusing on top tier customerscustomers

Major Players in Veterinary Major Players in Veterinary Vaccine MarketVaccine Market

Source: Company Annual Reports

Company Revenues from Animal

Health in 2010 ($ Bn)

Pfizer 3.575 Merck 2.900 Sanofi-Aventis 2.635 Bayer Healthcare 0.800 Virbac 0.781 Novartis 0.500 Boehringer Ingelheim 0.354 Heska Corporation 0.065

Salmogenics Salmogenics Competitive AdvantagesCompetitive Advantages

Patent positionsPatent positions Improved immune system of fowl = Improved immune system of fowl =

improved health and welfare of bird improved health and welfare of bird and humansand humans

Healthier chickens = healthier protein Healthier chickens = healthier protein sourcesource

Vaccine injected directly into egg = Vaccine injected directly into egg = reduced time and labor costsreduced time and labor costs

End result = success of SalmogenicsEnd result = success of Salmogenics

TimelineTimeline 1986 – Dr. Sotomayor began research on animal 1986 – Dr. Sotomayor began research on animal

health vaccineshealth vaccines 1995 – Technology brought to U.S.1995 – Technology brought to U.S. 1997 – USDA approved validation study begins1997 – USDA approved validation study begins 2008 – NHIL secures worldwide rights to 2008 – NHIL secures worldwide rights to

SalmogenicsSalmogenics 2010 – Studies as required by USDA contracted to 2010 – Studies as required by USDA contracted to

AHPharmaAHPharma 2010 – NHIL grants Salmogenics rights to Global 2010 – NHIL grants Salmogenics rights to Global

GreenGreen Feb 2011 – USDA Phase 4 trials beganFeb 2011 – USDA Phase 4 trials began May 2011 – Receive patent on vaccine compositionMay 2011 – Receive patent on vaccine composition

Timeline Timeline (cont(cont’’d)d) Aug 2011 – Receive patent on method and Aug 2011 – Receive patent on method and

composition composition Oct 2011 – SEC approves Form S-1 (IPO) Oct 2011 – SEC approves Form S-1 (IPO) Nov 2011 – Phase 4 Salmonella challenge Nov 2011 – Phase 4 Salmonella challenge

study completedstudy completed March 2012 – FINRA approvalMarch 2012 – FINRA approval March 2012 – Final report on Phase 4 March 2012 – Final report on Phase 4

Efficacy/Challenge studyEfficacy/Challenge study April 2012 – DTC application filedApril 2012 – DTC application filed April/May - USDA-approved production April/May - USDA-approved production

facility to be chosenfacility to be chosen

The Management TeamThe Management TeamNameName FunctionFunctionDr. Mehran Ghazvini, DC,NMDDr. Mehran Ghazvini, DC,NMD Chairman, Chairman,

CEOCEOand Treasurerand Treasurer

Dr. Rene Reed, DC, NMD Dr. Rene Reed, DC, NMD VP, SecretaryVP, Secretaryand Directorand Director

Investment HighlightsInvestment Highlights Worldwide Market OpportunityWorldwide Market Opportunity Proprietary Patent PositionsProprietary Patent Positions Focused on Contributing to Human Focused on Contributing to Human

Welfare through Technology in Welfare through Technology in Vaccines and other NutraceuticalsVaccines and other Nutraceuticals

Well Positioned for the FutureWell Positioned for the Future American-MadeAmerican-Made